We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Healthcare is timely and personal – and its delivery should be too
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Based on a post hoc analysis, fewer required respiratory interventions
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
The second phase of the orientation workshop is being organized to provide in-depth knowledge to the state officials on core building blocks of ABDM
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
